ArticlePeerJ2019
Integrated analysis of two-lncRNA signature as a potential prognostic biomarker in cervical cancer: a study based on public database.
Article in PeerJ, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Integrative Long Non-Coding RNA Analysis and Recurrence Prediction in Cervical Cancer Using a Recurrent Neural Network.Diagnostics (Basel, Switzerland) · 2025Article
- The pseudogenes of eukaryotic translation elongation factors (EEFs): Role in cancer and other human diseases.Genes & diseases · 2022Review
- Systematic analyses of a novel circRNA-related miRNAs prognostic signature for Cervical Cancer.Genetics and molecular biology · 2022Article
- Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer.Frontiers in genetics · 2022Article
- Mechanism underlying long non‑coding RNA ILF3‑AS1‑mediated inhibition of cervical cancer cell proliferation, invasion and migration, and promotion of apoptosis.Molecular medicine reports · 2021Article
- Identification of autophagy-related risk signatures for the prognosis, diagnosis, and targeted therapy in cervical cancer.Cancer cell international · 2021Article
- LncRNA LINC01305 promotes cervical cancer progression through KHSRP and exosome-mediated transfer.Aging · 2021Article
- Ginsenoside Rh7 Suppresses Proliferation, Migration and Invasion of NSCLC Cells Through Targeting ILF3-AS1 Mediated miR-212/SMAD1 Axis.Frontiers in oncology · 2021Article
- A five-mRNA signature associated with post-translational modifications can better predict recurrence and survival in cervical cancer.Journal of cellular and molecular medicine · 2020Article
- Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer.Cancer medicine · 2020Article
- Aberrant Expression of Long Non-coding RNAs in Exosomes in Follicle Fluid From PCOS Patients.Frontiers in genetics · 2020Article
- A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer.Frontiers in pharmacology · 2020Article
- Integrated Analysis of a Risk Score System Predicting Prognosis and a ceRNA Network for Differentially Expressed lncRNAs in Multiple Myeloma.Frontiers in genetics · 2020Article
- Six-lncRNA Immune Prognostic Signature for Cervical Cancer.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer (CC) is a common gynecological malignancy in women worldwide. Evidence suggests that long non-coding RNAs (lncRNAs) can be used as biomarkers in patients with CC. However, prognostic biomarkers for CC are still lacking. The aim of our study was to find lncRNA biomarkers which are able to predict prognosis in CC based on the data from The Cancer Genome Atlas (TCGA).
methodsThe patients were divided into three groups according to FIGO stage. Differentially expressed lncRNAs were identified in CC tissue compared to adjacent normal tissues based on a fold change >2 and <0.5 at
resultsIn total, 289 RNA sequencing profiles and accompanying clinical data were obtained. We identified 49 differentially expressed lncRNAs, of which two related to overall survival (OS) in CC patients. These two lncRNAs (ILF3-AS1 and RASA4CP) were found together as a single prognostic signature. Meanwhile, the prognosis of patients with low-risk CC was better and positively correlated with OS (
conclusionsOur study showed that the two-lncRNA signature of ILF3-AS1 and RASA4CP can be used as an independent biomarker for the prognosis of CC, based on bioinformatic analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.